Mayo Clinic Laboratory and Pathology Research Roundup: July 4
The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including a featured article of the week, abstracts, and complete list of published studies and reviews.
Featured Study of the Week
Hepatocellular carcinoma (HCC) is a global problem and the second most common cause of cancer-related deaths in the world. Its global incidence has been reported to be on the rise and is predicted to exceed one million cases per year by 2025. In a recent review, published in the Journal of Hepatology, Mayo Clinic researchers examined the clinical implications of current basic research in HCC. Currently, the overall survival of patients with HCC is bleak: less than 15% will live more than five years. This is largely due to the fact that a majority of HCCs are diagnosed at advanced stages when patients are not eligible for curative therapies such as resection or transplantation. And, advanced HCCs are resistant to most standard chemotherapy regimens.
Published to PubMed This Week
- Multiple Sclerosis Patients Have a Distinct Gut Microbiota Compared to Healthy Controls
- Custom Gene Capture and Next Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma
Journal of Thoracic Oncology
- Closure of a Recurrent Bronchopleural Fistula Using a Matrix Seeded With Patient-Derived Mesenchymal Stem Cells
Stem Cells Translational Medicine
- Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer
Annals of Surgical Oncology
- Oncocytic Variant of Malignant Gastrointestinal Neuroectodermal Tumor: A Potential Diagnostic Pitfall
- Influence of Neck Laceration Protectors on Cervical Range of Motion
Clinical Journal of Sport Medicine